Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Mean pre-chemotherapy counts/mm 2 of tumor infiltrating lymphocytes subpopulations and CD68 for the whole group of patients and comparison between responding and non-responding patients

From: Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer

TIL/mm 2Mean ± SD Whole group pCR Non pCR P a
CD3 cells     
  Pre-CT 172.33 ± 334.50 324.33 ± 233.18 138.26 ± 345.70 0.0004
  (n = 71) (n = 13) (n = 58)  
  Post-CT 100.43 ± 117.43 94.98 ± 158.88 101.74 ± 106.58 0.25
  (n = 88) (n = 17) (n = 71)  
  Absolute variation −78.46 ± 360.56 −259.59 ± 249.85 −37.87 ± 370.61 0.001
  (post-CT)-(pre-CT) (n = 71) (n = 13) (n = 58)  
  Relative variation, % 2459.63 ± 6403.11 281.52 ± 1242.71 2947.83 ± 6978.61 0.002
CD4 cells     
  Pre-CT 67.33 ± 123.89 146.94 ± 161.77 48.44 ± 106.28 0.003
  (n = 73) (n = 14) (n = 59)  
  Post-CT 21.99 ± 69.64 58.38 ± 145.88 13.27 ± 27.66 0.31
  (n = 88) (n = 17) (n = 71)  
  Absolute variation −52.28 ± 122.94 −119.93 ± 175.28 −36.23 ± 102.52 0.01
  (post-CT)-(pre-CT) (n = 73) (n = 14) (n = 59)  
  Relative variation, % 541.63 ± 1817.60 902.63 ± 3590.52 455.97 ± 1082.89 0.03
CD8 cells     
  Pre-CT 30.25 ± 101.97 3.58 ± 12.93 36.03 ± 111.65 0.15
  (n = 73) (n = 13) (n = 60)  
  Post-CT 37.03 ± 66.65 65.61 ± 121.59 30.28 ± 43.95 0.35
  (n = 89) (n = 17) (n = 72)  
  Absolute variation 3.75 ± 110.74 39.42 ± 46.51 −3.97 ± 119.10 0.08
  (post-CT)-(pre-CT) (n = 73) (n = 13) (n = 60)  
  Relative variation, % 2650.38 ± 3563.74 4294.12 ± 4085.8 2294.24 ± 3373.26 0.08
FOXP3 cells     
  Pre-CT 6.97 ± 17.98 8.37 ± 9.26 6.63 ± 19.53 0.01
  (n = 68) (n = 13) (n = 55)  
  Post-CT 16.51 ± 85.56 53.73 ± 190.42 7.60 ± 19.86 0.82
  (n = 88) (n = 17) (n = 71)  
  Absolute variation 0.4859 + 23.03 1.17 ± 27.44 0.32 ± 22.15 0.12
  (post-CT)-(pre-CT) (n = 68) (n = 13) (n = 55)  
  Relative variation, % 372.91 ± 1317.91 269.25 ± 901.21 397.411 ± 1404.04 0.08
CD20 cells     
  Pre-CT 42.08 ± 83.05 92.82 ± 94.10 30.71 ± 76.73 0.000
  (n = 71) (n = 13) (n = 58) 2
  Post-CT 14.17 ± 53.89 40.83 ± 119.40 7.79 ± 11.70 0.73
  (n = 88) (n = 17) (n = 71)  
  Absolute variation −33.86 ± 78.03 −81.31 ± 86.12 −23.23 ± 72.71 0.01
  (post-CT)-(pre-CT) (n = 71) (n = 13) (n = 58)  
  Relative variation, % 296.45 ± 782.61 −45.09 ± 95.39 373.00 ± 847.17 0.002
CD68 cells     
  Pre-CT 33.92 ± 45.09 55.65 ± 65.73 28.60 ± 37.48 0.12
  (n = 61) (n = 12) (n = 49)  
  Post-CT 39.08 ± 70.77 19.44 ± 23.52 43.51 ± 76.98 0.61
  (n = 87) (n = 16) (n = 71)  
  Absolute variation −7.04 ± 58.85 −36.93 ± 62.27 0.27 ± 56.24 0.02
  (post-CT)-(pre-CT) (n = 61) (n = 12) (n = 49)  
  Relative variation, % 340.13 ± 1132.29 −1.03 ± 159.41 423.68 ± 1249.23 0.16
  1. aMann–Whitney U-test. CT, chemotherapy; n, number; pCR, pathological complete response; SD, standard deviation; TIL, tumor infiltrating lymphocytes.